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1. Introduction 
We investigated the relationship between the occurrence of dobutamine-induced 
mechanical alternans (MA) and prognosis in ambulatory patients with idiopathic dilated 
cardiomyopathy (IDCM). 
Recent American College of Cardiology and American Heart Association guidelines for the 
management of heart failure have emphasized the need for earlier identification and 
therapy for patients at high risk of systolic dysfunction, as well as for those with 
symptomatic heart failure. 
MA, a condition characterized by beat-to-beat oscillation in the strength of cardiac muscle 
contraction at a constant heart rate, has been observed in patients with severe heart failure 
and in animal models of this condition. 
Although MA is rare under resting conditions in individuals with controlled heart failure, at 
higher heart rates it is more prevalent and likely to be sustained, as exemplified by pacing-
induced MA or dobutamine-induced MA. However, few studies have addressed the clinical 
implications of dobutamine-induced MA in patients with heart failure. We therefore 
prospectively examined the prognostic value of dobutamine- and pacing- induced MA in 
ambulatory patients with IDCM in sinus rhythm.(1) 
2. Methods 
2.1 Patient population 
We studied 90 patients with IDCM (mean age, 50 years; range, 20 to 76 years) and an New 
York Heart Association (NYHA) functional class of I or II. Thirty-eight of the patients had 
previously been admitted to hospital because of heart failure with dyspnea on exertion, 
palpitations, or peripheral edema, whereas the remaining 52 were asymptomatic and were 
identified on the basis of electrocardiogram abnormalities detected at annual health 
checkups. All patients had normal sinus rhythms. IDCM was defined by the presence of 
both a reduced left ventricular (LV) ejection fraction (<50%, as determined by contrast left 
ventriculography) and a dilated LV cavity. 
2.2 Cardiac catheterization 
All patients initially underwent routine diagnostic left and right heart catheterization. A 6F 
fluid-filled pigtail catheter with a high-fidelity micromanometer was advanced into the left 
ventricle through the right radial artery to measure LV pressure. Right atrial pacing was 
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initiated at 80 beats per minute (bpm) and was increased in increments of 10 bpm. We 
selected steady-state LV pressure data for at least 2 min at the baseline and at each pacing 
rate for analysis.(2) We calculated the maximum first derivative of LV pressure (LV dP/dtmax) 
as an index of contractility. To evaluate LV isovolumic relaxation, we computed the 
pressure half-time (T1/2) directly, as previously described.(3) The peak pacing rate was 
defined as the heart rate at which second-degree atrioventricular block occurred. After the 
hemodynamic values had returned to baseline, dobutamine was infused intravenously at 
incremental doses of 5, 10, and 15 µg kg–1 b.w. min–1 and hemodynamic measurements were 
performed at the end of each 5-min infusion period. MA was diagnosed if the pressure 
difference between the strong and weak beats was 4 mm Hg continuously in the analyzed 
LV pressure data, as previously described.(4) 
2.3 Quantitative RT-PCR analysis 
Quantitative reverse transcription (RT) and polymerase chain reaction (PCR) analysis of the 
mRNAs for sarcoplasmic reticulum Ca2+-ATPase (SERCA2a), ryanodine receptor 2, 
phospholamban, calsequestrin, and the Na+-Ca2+ exchanger was performed as previously 
described.(5) The amount of each mRNA was normalized against the corresponding amount 
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. 
2.4 Follow-up 
We prospectively followed up all patients for the occurrence of primary events, which were 
defined as cardiac death (death from worsening heart failure or sudden death), unscheduled 
hospital readmission for worsening heart failure, or receipt of an implantable cardioverter 
defibrillator (ICD) because of life-threatening arrhythmia. 
3.Results 
3.1 Classification of IDCM patients on the basis of MA 
To identify on the basis of the classification by hemodynamic response to pacing or 
dobutamine stress testing, patients were classified into three groups: those who exhibited 
neither pacing- nor dobutamine-induced MA (n = 60, group N), those who manifested only 
pacing-induced MA (n = 20, group P), and those who developed both pacing- and 
dobutamine-induced MA (n = 10, group D). All patients who did not develop pacing-
induced MA also did not exhibit dobutamine-induced MA. LV pressure waveforms during 
atrial pacing at 120 bpm or after dobutamine infusion at 10 µg kg–1 min–1 are shown for 
representative patients from each group (Fig. 1). 
3.2 Baseline clinical data 
There were no significant differences in age and sex among the three groups of patients 
(Table 1). All patients were classified as NYHA functional class I or II at the time of cardiac 
catheterization. The LV ejection fraction (LVEF) in groups P and D was significantly lower 
than that in group N. There were also no significant differences in plasma brain natriuretic 
peptide (BNP) or norepinephrine levels among the three groups. 
3.3 Abundance of Ca2+-handling protein mRNAs in endomyocardial biopsy specimens 
The amounts of Ca2+-handling protein mRNAs in endomyocardial biopsy specimens were 
determined by using quantitative RT-PCR and were normalized against that of GAPDH 
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mRNA (Table 2). The abundance of phospholamban mRNA was significantly lower in 
group D than in group P. The SERCA2a/phospholamban mRNA ratio was significantly 




















Fig. 1. LV pressure waveforms during atrial pacing at 120 bpm and after infusion of 
dobutamine at a dose of 10 µg kg–1 min–1 in representative patients of three study groups. 
The traces represent the lead II electrocardiogram (ECG), LV pressure, and LV dP/dt. Both 
LV dP/dtmax and LV dP/dtmin showed alternating changes with LV pressure. Strong and 
weak beats are indicated by s and w, respectively. 
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Group N  
(n = 60) 
Group P  
(n = 20) 
Group D (n = 10) 
Age (years) 51 ± 12 50 ± 13 45 ± 11 
Sex (M/F) 44 / 16 16 / 4 6 / 4 
NYHA functional class I  32 (53%) 9 (45%) 5 (50%) 
   class II  28 (47%) 11 (55%) 5 (50%) 
Medication           
 Diuretics 30 (50%) 17* (85%) 9* (90%) 
 ACE inhibitors or ARBs 42 (70%) 19 (95%) 7 (70%) 
 Beta blockers 22 (37%) 10 (50%) 5 (50%) 
PAWP (mmHg) 10.7 ± 4.7 14.6 ± 6.2* 13.9 ± 7.2 
Cardiac index (L min–1 m–2) 3.07 ± 
0.5
5 
2.83 ± 0.58 3.26 ± 0.66 
LVEF (%) 38.9 ± 8.1 32.9 ± 9.6* 30.3 ± 9.0* 
Plasma BNP (pg/mL) 100 ± 173 179 ± 186 249 ± 262 
Plasma norepinephrine 
(pg/mL) 
440 ± 221 689 ± 764 664 ± 324 
*P < 0.05 versus group N. Abbreviations not defined in text: ACE, angiotensin-converting enzyme; ARB, 
angiotensin-II receptor blocker; PAWP, pulmonary artery wedge pressure. 
Table 1. Baseline clinical characteristics of patients in the three study groups 
 
mRNA ratio Group N Group P Group D 
SERCA2a/GAPDH 0.42 ± 0.15 0.41 ± 0.13 0.43 ± 0.13 
Phospholamban/GAPDH 0.82 ± 0.45 1.01 ± 0.13 0.42 ± 0.24* 
Ryanodine receptor 2/GAPDH 0.50 ± 0.19 0.53 ± 0.21 0.75 ± 0.17 
SERCA2a/phospholamban 0.63 ± 0.31 0.59 ± 0.40 1.32 ± 0.95*† 
SERCA2a/Na+-Ca2+ 
exchanger 
0.57 ± 0.79 0.50 ± 0.56 0.27 ± 0.14 
*P < 0.05 versus group P, †P < 0.05 versus group N.  
Table 2. Quantitative RT-PCR analysis of the abundance of Ca2+-handling protein mRNAs in 
endomyocardial biopsy specimens. 
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3.4 Follow-up evaluation and event-free survival 
Of the 90 patients who were followed up, 4 individuals (4%) experienced cardiac death, 10 
(11%) manifested worsening heart failure, and 4 (4%) received ICDs. The probability of 
event-free survival in group D was significantly lower than that in groups N or P (P = 0.002) 
(Fig. 2). 
3.5 Univariate and multivariate analysis of cardiac events 
Univariate analysis revealed that dobutamine-induced MA, pacing-induced MA, NYHA 
functional class, plasma BNP levels, mitral regurgitation, pulmonary artery wedge pressure, 
LV end-diastolic volume index, LV end-systolic volume index, LVEF, LV end-diastolic 
pressure and T½ were significant predictors of cardiac events (Table 3). Then, stepwise 
multivariate analysis identified dobutamine-induced MA (odds ratio, 4.05; 95% confidence 
interval, 1.35 to 12.2) as a significant independent predictor of cardiac events (Table 4). Both 
T1/2 (odds ratio, 1.079; 95% confidence interval, 1.003 to 1.161) and plasma BNP level (odds 
ratio, 1.002; 95% confidence interval, 1.0004 to 1.0038) were also significant independent 







Fig. 2. Kaplan-Meier analysis of the cumulative probability of event-free survival of the 90 
IDCM study patients. The probability of event-free survival in group D was significantly 
lower than that in groups P and N by the log-rank test (P = 0.002).  
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Univariate analysis  
Event-free group Cardiac-event group  
(n = 72) (n = 18 ) P 
Dobutamine-induced MA 
(group D/groups P and N) 
4 / 68 6 / 12 0.0019 
Pacing-induced MA 
(groups D and P/group N)  
20 / 52 10 / 8 0.04 
Age (years) 50 ± 12 53 ± 14 0.34 
Sex (M/F) 53 / 19 13 / 5 0.86 
Body mass index (kg/m2) 24.4 ± 4.9 22.5 ± 2.6 0.15 
NYHA functional class  1.3 ± 0.5 1.6 ± 0.4 0.011 
QRS duration (ms) 113 ± 27 112 ± 22 0.88 
Beta blockers  55 (76%) 10 (56%) 0.58 
Diuretics 52 (72%) 16 (89%) 0.88 
Plasma BNP (pg/mL) 123 ± 238 228 ± 162 0.0013 
eGFR (mL min–1 1.73 m–2) 74 ± 17 68 ± 18 0.089 
Plasma norepinephrine 
(pg/mL) 
521 ± 452 524 ± 292 0.32 
Mitral regurgitation  0.56 ± 0.64 0.94 ± 0.94 0.022 
E/E’ 15.6 ± 8.6 24.2 ± 8.4 0.227 
PAWP (mmHg) 11.5 ± 5.3 13.7 ± 6.6 0.044 
Cardiac index (L min–1 m–2) 3.02 ± 0.57 3.13 ± 0.64 0.85 
LVEDVI (mL m–2) 73 ± 52 115 ± 79 0.02 
LVESVI (mL m–2) 43 ± 36 84 ± 62 0.018 
LVEF (%) 38.2 ± 8.7 32.8 ± 6.8 0.003 
Heart rate (bpm) 76 ± 17 75 ± 14 0.34 
LVEDP (mmHg) 12 ± 8 15 ± 9 0.019 
LVSP (mmHg) 119 ± 19 116 ± 23 0.62 
LV dP/dtmax (mmHg/s) 1114 ± 263 1160 ± 263 0.73 
T1/2 (ms) 39 ± 7 44 ± 4.7 0.0086 
Table 3. Univariate of predictors of cardiac events. 
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 β OR ( 95% CI ) P 
Dobutamine-induced MA 
(group D/groups P and N) 
1.4 4.05 (1.35–12.2) 0.0126 
Plasma BNP (pg/mL) 0.0021 1.002 (1.0004–1.0038) 0.014 
T1/2 (ms) 0.076 1.079 (1.0033–1.161) 0.041 
Table 4. Multivariate analysis of predictors of cardiac events. 
4. Discussion 
We found that the occurrence of dobutamine-induced MA was a clinical predictor of poor 
prognosis in ambulatory patients with IDCM in sinus rhythm. Although there was no 
significant difference in LVEF between patients who manifested only pacing-induced MA 
and those who developed both pacing- and dobutamine-induced MA, the probability of 
event-free survival in the latter group was significantly lower than that in the former. 
Multivariate analysis also revealed that the occurrence of dobutamine-induced MA was a 
significant independent predictor of cardiac events. 
Our study included a group of 90 ambulatory patients with IDCM (mean LVEF of 36.5% 
and plasma BNP concentration of 132 pg/mL). We sought to investigate whether the 
hemodynamic response to dobutamine stress testing was associated with prognosis in 
such patients and could thereby serve as a physiological phenomenon on which risk 
stratification could be based. Three general mechanisms have been proposed to account 
for the development of MA: alteration of action potential duration, impaired ventricular 
relaxation, and abnormal intracellular Ca2+ handling.(6) The low relative ratio of 
phospholamban to SERCA reduces the inhibition of SERCA and increases Ca2+ -uptake; 
this enhances relaxation and contraction in the human atrium. However, humans lacking 
phospholamban develop lethal IDCM.(7) SERCA2a and ryanodine receptor 2 mRNA 
levels were similar in all three of our groups, whereas the relative ratio of SERCA to 
phospholamban was significantly higher in patients with pacing- and dobutamine-
induced MA than in those with only pacing-induced MA or with no MA. Our results 
suggest that an imbalance between phospholamban and SERCA mRNA levels in the 
abundant Ca2+-handling proteins is associated with dobutamine-induced MA. We also 
recently found that the amounts of mRNAs for the β1-adrenergic receptor and SERCA2a 
in the myocardium were smaller in asymptomatic or mildly symptomatic IDCM patients 
with reduced adrenergic myocardial contractile reserve than in those with preserved 
adrenergic contractile reserves.(8) The occurrence of dobutamine-induced MA in our 
patients in the present study might also reflect abnormal β1-adrenergic receptor signaling 
in the myocardium. However, steady-state mRNA levels do not necessarily reflect the 
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corresponding protein levels, in particular because both mRNA and protein synthesis or 
degradation may be altered in the failing heart.(9, 10) Further studies are needed to 
elucidate these issues. 
In patients with heart failure, dobutamine-induced MA is highly prevalent(4) and 
mechanical and visible T-wave alternans is detectable under tachycardia or 
catecholamine exposure.(2, 11) Dobutamine-induced MA may be attributed various 
factors, including an increase in the heart rate as a result of dobutamine infusion, 
impaired LV contraction, the influence of preload, and abnormal Ca2+ under 
pathophysiological conditions. Dobutamine is a β-stimulator that increases both heart 
rate (HR) and LV contraction. The increase in HR, but not that in LV contraction, is likely 
to be a trigger for the occurrence of dobutamine-induced MA. Therefore, the increased 
occurrence of dopamine-induced MA in heart failure patients might be related to their 
poor myocardial contractile reserve 
We reported previously that the occurrence of pacing-induced MA is a potentially useful 
indicator of poor prognosis in patients with mild-to-moderate IDCM in sinus rhythm.(2) 
Here, we found that, among our ambulatory IDCM patients, those with both pacing- and 
dobutamine-induced MA had the least favorable clinical course, whereas those with only 
pacing-induced MA had a moderate clinical course, even though the mean value of baseline 
LVEF did not differ significantly between these two groups. 
Our results show that the occurrence of dobutamine-induced MA is a potentially useful 
clinical predictor of cardiac events in ambulatory patients with IDCM in sinus rhythm. 
Recent guidelines for the management of heart failure emphasize the need for earlier 
identification of and therapy for patients who are at high risk of developing heart failure or 
who have asymptomatic LV systolic dysfunction.(12) We showed here that the prevalence of 
cardiac events or cardiac death was higher in patients with dobutamine- and pacing- 
induced MA than in those without it. Assessment of dobutamine-induced MA in addition to 
routine clinical evaluation in patients with IDCM may thus contribute to stratification of 
individuals into low- or high-risk groups. 
Our study had several limitations. First, it included only a small number of patients. 
Second, the identification of pacing- or dobutamine-induced MA requires an invasive 
examination and time-consuming hemodynamic stress assessment. The current trend in 
clinical medicine is to find a non-invasive test with prognostic consequences. However, 
these results of the present study suggested that the hemodynamic phenomenon by 
dobutamine stress testing might be also potentially useful marker for predicting the 
occurrence of cardiac events. The fact that such examinations are not amenable to being 
repeated over time is a potential limitation of their prognostic utility. Whether our 
findings will also hold for patients with more severe heart failure requires further 
investigation. 
In conclusion, the occurrence of dobutamine-induced MA is a potentially useful clinical 
predictor of poor prognosis in ambulatory patients with IDCM in sinus rhythm. 
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